Evolutionary Dynamics of the Glycan Shield of theHuman Immunodeficiency Virus Envelope during Natural Infection andImplications for Exposure of the 2G12Epitope
Open Access
- 15 November 2004
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 78 (22) , 12625-12637
- https://doi.org/10.1128/jvi.78.22.12625-12637.2004
Abstract
Elucidation of the kinetics of exposure of neutralizing epitopes on the envelope of human immunodeficiency virus type 1 (HIV-1) during the course of infection may provide key information about how HIV escapes the immune system or why its envelope is such a poor immunogen to induce broadly efficient neutralizing antibodies. We analyzed the kinetics of exposure of the epitopes corresponding to the broadly neutralizing human monoclonal antibodies immunoglobulin G1b12 (IgG1b12), 2G12, and 2F5 at the quasispecies level during infection. We studied the antigenicity and sequences of 94 full-length envelope clones present during primary infection and at least 4 years later in four HIV-1 clade B-infected patients. No or only minor exposure differences were observed for the 2F5 and IgG1b12 epitopes between the early and late clones. Conversely, the envelope glycoproteins of the HIV-1 quasispecies present during primary infection did not expose the 2G12 neutralizing epitope, unlike those present after several years in three of the four patients. Sequence analysis revealed major differences at potential N-linked glycosylation sites between early and late clones, particularly at positions known to be important for 2G12 binding. Our study, in natural mutants, confirms that the glycosylation sites N295, N332, and N392 are essential for 2G12 binding. This study demonstrates the relationship between the evolving “glycan shield ” of HIV and the kinetics of exposure of the 2G12 epitope during the course of natural infection.Keywords
This publication has 72 references indexed in Scilit:
- A Sound Rationale Needed for Phase III HIV-1 Vaccine TrialsScience, 2004
- Interclade Neutralization and Enhancement of Human Immunodeficiency Virus Type 1 Identified by an Assay Using HeLa Cells Expressing Both CD4 Receptor and CXCR4/CCR5 CoreceptorsThe Journal of Infectious Diseases, 2004
- A Novel Human Antibody against Human Immunodeficiency Virus Type 1 gp120 Is V1, V2, and V3 Loop Dependent and Helps Delimit the Epitope of the Broadly Neutralizing Antibody Immunoglobulin G1 b12Journal of Virology, 2003
- Antibody neutralization and escape by HIV-1Nature, 2003
- Caloramator viterbensis sp. nov., a novel thermophilic, glycerol-fermenting bacterium isolated from a hot spring in ItalyInternational Journal of Systematic and Evolutionary Microbiology, 2002
- A Potent Cross-Clade Neutralizing Human Monoclonal Antibody against a Novel Epitope on gp41 of Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 2001
- Comparison of Complete env Gene Sequences from Individuals with Symptomatic Primary HIV Type 1 InfectionAIDS Research and Human Retroviruses, 1999
- Analysis of the Interaction of Antibodies with a Conserved, Enzymatically Deglycosylated Core of the HIV Type 1 Envelope Glycoprotein 120AIDS Research and Human Retroviruses, 1998
- Augmented Serum Neutralizing Activity against Primary Human Immunodeficiency Virus Type 1 (HIV‐1) Isolates in Two Groups of HIV‐1‐Infected Long‐Term NonprogressorsThe Journal of Infectious Diseases, 1997
- CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choiceNucleic Acids Research, 1994